Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery

Area of Science:

• Ocular drug delivery
• Nanotechnology in pharmaceuticals
• Biomaterials science

Background:

• Cyclosporine A (CsA) is crucial for treating ocular inflammatory conditions.
• Conventional CsA formulations face challenges in ocular penetration and sustained release.
• Solid lipid nanoparticles (SLNs) offer a promising platform for improving drug delivery.

Purpose of the Study:

• To develop and characterize cationic solid lipid nanoparticles (SLNs) for ocular delivery of Cyclosporine A (CsA).
• To evaluate the physicochemical stability and in vivo ocular penetration of CsA-loaded SLNs.
• To assess the release profile and residence time of CsA from SLNs in ocular tissues.

Main Methods:

• Incorporation of CsA into cationic SLNs using Dynasan 116 structured FD4.
• Physicochemical characterization including particle size, polydispersity index (PI), and zeta potential.
• In vivo ocular application in sheep, followed by sample collection and analysis using enzyme immune assay (EIA).

Main Results:

• Optimized SLNs exhibited small particle size (248 nm), narrow distribution (PI=0.25), and high positive zeta potential (50.3 mV).
• CsA was detected in aqueous and vitreous humor for 48 hours post-application, confirming ocular penetration.
• Formulation showed sustained and prolonged release of CsA over 48 hours, attributed to increased residence time.

Conclusions:

• Cationic SLNs provide an effective system for ocular delivery of Cyclosporine A.
• The developed SLN formulation ensures prolonged drug presence in ocular tissues, enhancing therapeutic potential.
• This nanotechnology-based approach overcomes limitations of conventional CsA delivery for ocular diseases.